Epilepsy Devices Market: Tech Trends, Forecast 2022-2028

1
Epilepsy Devices Market Tech Trends
2022-2028 Lifesciences 09, December 2022
According to the WHO, epilepsy is a
chronic brain disorder that affects 50
million individuals, making it one of the
most prevalent neurological conditions
worldwide. It is estimated that with access
to early detection and appropriate care,
70 of the population diagnosed with
epilepsy may live seizure-free. According to
our estimates, the global epilepsy devices
market was valued at 669.73 million in
2021 and is expected to reach 1157.58
million by 2028, growing at a CAGR of 8.16
during the forecast period 2022-
2028. Government institutions worldwide are
focused on starting initiatives to create
innovative epilepsy devices with AI and machine
learning integration. Additionally, organizations
that support research need to encourage
high-quality comparative efficacy trials and
sufficient data to guide therapeutic practice in
epilepsy. As a result of these technologically
advanced equipment and increasing drug trials,
the market for epilepsy devices is anticipated to
grow throughout the forecast period. Epilepsy
Devices - Key Detection Methodologies
2

• Currently, several wearable technologies
  can detect seizures, collect data, and
  alert caregivers. Although with technological
  advancements, the ability to detect
  seizure-related alterations increases. Top trends
  backing this tech boom include
• Wearable devices are estimated to be the
  fastest-growing device type during the
  forecast period. Monitoring epileptic
  patients is crucial, as 20 of epileptics
  only have seizures while asleep, 40 only
  have seizures while awake, and 35 have
  seizures both when they are awake and asleep.
  With technologically advanced non- invasive
  wearable sensors, measuring accelerometry,
  photoplethysmography (PPG), electrodermal
  activity (EDA), electromyography (EMG), and other
  signals outside of the conventional clinical
  environment have become effective.
• Vagus Nerve Stimulation (VNS) has emerged
  as the fastest-growing application category.
  VNS Therapy has been approved by the
  U.S. Food and Drug
• Administration (FDA) as an add-on therapy for age
  4 years and above to treat drug- resistant
  epilepsy or refractory epilepsy. VNS has been
  reportedly beneficial in many patients,
  including the ones with posttraumatic
  epilepsy (PTE). PTE is a common consequence
  of traumatic brain injury and accounts for about
  20 of symptomatic epilepsy cases.
• As per estimates, Electroencephalography lead the
  detection and prediction devices type segment in
  2021 and is expected to maintain its stronghold
  during the forecast
• period. There is growing interest in
  wearable or mobile EEG solutions that allow
  long-term EEG monitoring in an easy-to-use
  format. Despite the availability of these new EEG
  solutions, their adoption is still limited in
  clinical practice, mainly because of the
  unfamiliarity of healthcare and biomedical
  research sectors with the technology and its
  application.
• Strategic Initiatives and Government Approvals
• Different end-users, such as homecare settings,
  hospitals, and clinics, are utilizing epilepsy
  devices. The manufacturers of epilepsy
  monitoring devices are likely to gain
  prominent business opportunities from the
  hospital clinics segment owing to the
  rise in the use of EEG monitoring and
  emergency medical services.
• The government authorities of several
  developing nations, including India and
  China, are focusing on developing sturdy
  healthcare infrastructure. As a result,
  operating players are expected to gain sizable
  growth prospects in the region during the
  forecast period. Owing to this, the Asia Pacific
  epilepsy devices market is anticipated to witness
  the fastest growth with a CAGR of 8.38
  throughout the forecast period.
• In addition, companies are also focusing on
  launching novel devices for children. Moreover,
  companies are also using organic and
  inorganic strategies, including mergers
  and acquisitions, to stay ahead of the
  competition. Some of these include
• In September 2022, Boston
  Scientific Corporations
  current-generation WATCHMAN FLX Left Atrial
  Appendage Closure (LAAC) Device received U.S.
  Food and Drug Administration (FDA) approval
  to expand the instructions for use labeling.
  The company also received FDA 510(k) clearance
  for the EMBOLD Fibered Detachable Coil, which
  reduces the blood flow rate in the peripheral
  vasculature.
• In July 2022, Medtronic PLC received FDA
  510(k) clearance for its UNiD Spine Analyzer
  v4.0 planning platform to leverage machine
  learning.

3

• In November 2021, NeuroPace, Inc. received
  an Investigational Device Exemption (IDE) from
  the FDA to study the companys RNS System to
  treat primary generalized epilepsy in patients
  aged 12 and above.
• Way Forward
• With technological advancements, epilepsy
  detection devices with exceptionally low
  false alarm rates have recently been
  developed. They are based on computationally
  intensive algorithms and employed in implanted
  systems for pre-surgical monitoring. Recent
  research has produced encouraging findings for
  probabilistic seizure risk projections using
  long-term wearable technology and electronic
  seizure diaries. The symptoms, mood, and
  cognitive function of an individual may also
  have predictive significance. Therefore,
  technological advances in non-invasive wearable
  sensors are anticipated to create growth
  opportunities for the epilepsy devices market.

FAQ Q1) What are the key end-users of the
epilepsy devices market? The key end-users in
the epilepsy devices market include
hospitals clinics, neurology centers,
homecare settings, and other end-users. Q2) Which
region leads the global epilepsy devices market?
North America leads the global epilepsy devices
market.